{
    "nctId": "NCT01425294",
    "briefTitle": "Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment",
    "officialTitle": "A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 231,
    "primaryOutcomeMeasure": "To evaluate the effectiveness of Faslodex 250mg monthly to treat post-menopausal women with ER+ locally advanced or MBC in terms of progression-free survival (PFS), by collecting real world data according to Chinese physicians' clinical practice.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Chinese postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer Failure to previous anti-estrogen therapy, already received Faslodex 250mg treatment as determined by treating physician.\n* The prescription of the Faslodex is clearly separated from the decision to include the subject in the NIS, and is part of normal medical practice. The recruitment of the patient to the study should be within 1 month of the first Faslodex injection.\n* Provision of subject informed consent.\n\nExclusion Criteria:\n\n* If participating in any controlled clinical trial, the subject cannot take part in this study.\n* Hypersensitivity to the active substance, or to any of the other excipients.\n* Pregnancy and lactation, or severe hepatic impairment.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}